ES2603061T3 - Interrupción de la percepción de quórum en bacterias mediada por anticuerpos - Google Patents

Interrupción de la percepción de quórum en bacterias mediada por anticuerpos Download PDF

Info

Publication number
ES2603061T3
ES2603061T3 ES14180831.1T ES14180831T ES2603061T3 ES 2603061 T3 ES2603061 T3 ES 2603061T3 ES 14180831 T ES14180831 T ES 14180831T ES 2603061 T3 ES2603061 T3 ES 2603061T3
Authority
ES
Spain
Prior art keywords
seq
amino acid
kynp
hapten
cyclic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14180831.1T
Other languages
English (en)
Spanish (es)
Inventor
Kim D. Janda
Gunnar F. Kaufmann
Junguk Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of ES2603061T3 publication Critical patent/ES2603061T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES14180831.1T 2007-10-25 2008-10-24 Interrupción de la percepción de quórum en bacterias mediada por anticuerpos Active ES2603061T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98259307P 2007-10-25 2007-10-25
US982593P 2007-10-25

Publications (1)

Publication Number Publication Date
ES2603061T3 true ES2603061T3 (es) 2017-02-23

Family

ID=40580303

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14180831.1T Active ES2603061T3 (es) 2007-10-25 2008-10-24 Interrupción de la percepción de quórum en bacterias mediada por anticuerpos

Country Status (9)

Country Link
US (2) US9394371B2 (https=)
EP (2) EP2211889B1 (https=)
JP (3) JP5581490B2 (https=)
KR (1) KR101557173B1 (https=)
CN (2) CN101835484B (https=)
AU (1) AU2008317331B2 (https=)
CA (2) CA2975568A1 (https=)
ES (1) ES2603061T3 (https=)
WO (1) WO2009055054A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066677A1 (en) 2012-10-26 2014-05-01 Sorrento Therapeutics Inc. Anti-infective binding proteins that bind aip2
DE102013211850A1 (de) * 2013-06-21 2014-12-24 Gilupi Gmbh Schnelltest zum Nachweisen von Erregermaterial, insbesondere zur Unterstützung der Diagnose einer Sepsis, sowie Kit und Vorrichtung zur Durchführung eines Sepsistests
ES2860952T3 (es) * 2013-08-01 2021-10-05 Univ Catholique Louvain Proteína anti-garp y usos de la misma
KR20160102210A (ko) 2013-12-27 2016-08-29 노버스 인터내쇼날 인코포레이티드 에톡시화 계면활성제
CN106459956B (zh) * 2014-01-29 2019-12-17 一般财团法人化学及血清疗法研究所 抗-运甲状腺素蛋白人抗体
KR102538555B1 (ko) 2014-01-29 2023-05-30 케이엠 바이올로직스 가부시키가이샤 항-트랜스티레틴 인간화 항체
EP3103808B1 (en) * 2014-02-07 2018-08-22 Miyarisan Pharmaceutical Co., Ltd. Peptide having activity of inhibiting production of toxin by bacterium belonging to genus clostridium
US10821167B2 (en) * 2016-02-02 2020-11-03 Unm Rainforest Innovations VLP-based vaccines for targeting Staphylococcus aureus secreted virulence factors
WO2018031730A2 (en) * 2016-08-11 2018-02-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
WO2018152452A1 (en) 2017-02-17 2018-08-23 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
MX2020002013A (es) * 2017-08-31 2020-07-13 Univ California Bacterioterapia molecular para control de la actividad enzimatica de la piel.
ES2960419T3 (es) 2017-09-15 2024-03-04 Lentigen Tech Inc Composiciones y métodos de tratamiento de cáncer con inmunoterapia anti-CD19
US10774135B2 (en) 2017-12-22 2020-09-15 Sorrento Therapeutics, Inc. Variant antibodies that bind AIP2
US11459445B2 (en) 2018-02-13 2022-10-04 Sumitomo Chemical Company, Limited Composition and molded body
CA3150161A1 (en) 2019-08-13 2021-02-18 Darlene E. MCCORD Non-activated, amorphous, ph neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals
CN111573853B (zh) * 2020-05-29 2020-11-20 南京大学 一种削减生物法处理废水毒性的方法
EP4423197A4 (en) 2021-10-25 2025-08-27 Darlene E Mccord COATED MEDICINAL CLAY COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND DELIVERY OF CATION SOURCES AND METHODS OF USE THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2256465A1 (en) * 1996-05-22 1997-11-27 New York University Blocking expression of virulence factors in s. aureus
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
JP2003532698A (ja) * 2000-05-10 2003-11-05 プリンストン ユニバーシティ 細菌の増殖および病理発生を調節するための化合物ならびに方法
US7786257B2 (en) * 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US6463632B2 (en) * 2001-02-07 2002-10-15 Hans Oetiker Ag Maschinen-Und Apparatefabrik Guide arrangement for tightening tool emplacement in hose clamps provided with plastically deformable ears
CN1164612C (zh) * 2001-09-11 2004-09-01 四川新泰克控股有限责任公司 人工组合的抗菌工程多肽及其制备方法
EP1528935B1 (en) * 2002-08-13 2012-03-21 Haptogen Ltd Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody

Also Published As

Publication number Publication date
CN101835484A (zh) 2010-09-15
EP2211889A2 (en) 2010-08-04
US20170043020A1 (en) 2017-02-16
EP2842565B1 (en) 2016-08-24
JP2011500814A (ja) 2011-01-06
JP2014221774A (ja) 2014-11-27
KR101557173B1 (ko) 2015-10-05
CN104211775A (zh) 2014-12-17
CA2703133C (en) 2017-09-19
EP2842565A1 (en) 2015-03-04
JP6183910B2 (ja) 2017-08-23
WO2009055054A2 (en) 2009-04-30
KR20100102100A (ko) 2010-09-20
JP2018021021A (ja) 2018-02-08
EP2211889B1 (en) 2014-08-20
AU2008317331B2 (en) 2013-08-29
EP2211889A4 (en) 2012-01-11
CA2975568A1 (en) 2009-04-30
JP5581490B2 (ja) 2014-09-03
WO2009055054A3 (en) 2009-09-03
AU2008317331A1 (en) 2009-04-30
US9394371B2 (en) 2016-07-19
US20100291093A1 (en) 2010-11-18
CA2703133A1 (en) 2009-04-30
CN101835484B (zh) 2014-07-16

Similar Documents

Publication Publication Date Title
ES2603061T3 (es) Interrupción de la percepción de quórum en bacterias mediada por anticuerpos
Yuan et al. Revised conodont-based integrated high-resolution timescale for the Changhsingian Stage and end-Permian extinction interval at the Meishan sections, South China
Yuanlong et al. Kaili Biota: a taphonomic window on diversification of metazoans from the basal Middle Cambrian: Guizhou, China
AR112768A1 (es) Anticuerpos anti-tigit
NZ609707A (en) A collection and methods for its use
AR111207A1 (es) Anticuerpos anti-lag3
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
PE20201255A1 (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos
JP2012527899A5 (https=)
CO6362024A2 (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
Hsueh et al. Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome, Taiwan
NZ608972A (en) Engineered nucleic acids and methods of use thereof
RU2014127308A (ru) Инженерия и оптимизация одноцепочечных антител на основе последовательности
AR102417A1 (es) Anticuerpos biespecíficos anti-tnf- / anti-il-23
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
CO6150192A2 (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos
AR038700A1 (es) Anticuerpos monoclonales anti-tenascina humana
WO2007143442A3 (en) A novel virulence determinant within the e2 structural glycoprotein of classical swine fever virus
JP2020502104A5 (https=)
CN101550189B (zh) 人源抗狂犬病毒糖蛋白中和性基因工程抗体rd9及其制备与应用
AR109857A1 (es) Anticuerpos anti-chikv y usos de éstos
CN109415438A (zh) 一类抗cd20靶向抗体及用途技术领域
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
EP1482795A4 (en) NEW IMMUNE EFFECTOR LINKS